【个人简介】
李艳丽，女，理学博士，南山学者特聘副教授。2021年毕业于华东师范大学，师从步文博教授；随后进入广州医科大学药学院工作。目前已在Angew. Chem. Int. Ed., ACS nano, Nano today等期刊共发表论文15篇。近五年来，以第一、共一或通讯作者身份发表论文11篇，7篇IF>10。
【联系邮箱】
ylli@gzhmu.edu.cn
【研究方向类别】
1、学术学位：药剂学、药物分析学、药理学
2、专业学位：临床药学（临床药理学）、工业药学（临床药剂学）
【具体研究方向】
1、无机及有机/无机杂化纳米材料的设计、合成及功能化
2、功能纳米材料介导的肿瘤治疗及免疫、抗菌研究
【主要科研项目】
1、国家自然科学基金青年项目，2023/01-2025/12，在研，主持
2、广州市科技局基础与应用基础研究项目，2023/04-2025/03，在研，主持
3、广州医科大学高水平大学人才引进项目，2022/01-2027/01，在研，主持
【主要论文及著作（代表性）】
1. Xiaowen Cai, Junming Li, Ruoqi Zhang, Jie Zhou, Hongmiao Lin, XiaohuaHuang, Chuanshan Xu*, Yanli Li*, and Teng Gong*. Homeostatic nanomedicine: Protein S-nitrosylation dyshomeostasis dominated oncotherapy based on a tumor-microenvironment-activated nanoparticle, Chem. Eng. J., 2024, 500,157029. (IF=13.3)
2. Shuangpiao Deng, Kaixin Ou, Chenyu Zhang, Daojing Yuan, Xiaowen Cai, Fengtan Li, Xuetao Wang, Jing Yin*, Chuanshan Xu*, Yanli Li*, and Teng Gong*. A one-two punch strategy for diabetic wound management based on an antibiotic-hybrid biomineralized iron sulfide nanoparticle, Acta Biomater., 2024, 181, 333-346. (IF=9.4)
3. Shulin Qin,Lichun Ma, Runfeng Li, Pengfei Yuan, Yunfeng Shi, Xin Ji, Wei Xue, Yanli Li*, and Wen Liu*. Multifunctional Ca2+ nanomodulators regulate type I interferon pathway to remodel tumor microenvironment for cancer immunotherapy, Chem. Eng. J., 2023, 477, 147118. (IF=13.3)
4. Jianwen Huang, Shuai Wang, You Zhou, Qiuxia Li, Jing Yin b, Dailong Zha, Junyang Zhong, Wenmin Zhou, Chengkun Zheng, Yingling Miao, Wenjie Chen, Chuanshan Xu*, Yanli Li*, and Teng Gong*. Nanoformulations mediated metastasis brake in cancer therapy via photodynamic-enhanced ferroptosis and regional inflammation management, Chem. Eng. J., 2023, 451, 138585. (IF=13.3)
5. Yanli Li, Teng Gong*, Hongbao Gao, Yang Chen, Huiyan Li, Peiran Zhao, Yaqin Jiang, Kun Wang, Yelin Wu, Xiangpeng Zheng*, and Wenbo Bu*. ZIF-Based Nanoparticles Combine X-Ray-Induced Nitrosative Stress with Autophagy Management for Hypoxic Prostate Cancer Therapy, Angew. Chem. Int. Ed., 2021, 60, 15472-15481. (IF=16.1)
6. Yanli Li, Peiran Zhao, Teng Gong*, Han Wang, Xingwu Jiang, Hui Cheng, Yanyan Liu, Yelin Wu*, and Wenbo Bu*. Redox Dyshomeostasis Strategy for Hypoxic Tumor Therapy Based on DNAzyme-Loaded Electrophilic ZIFs, Angew. Chem. Int. Ed., 2020, 59, 22537-22543. (IF=16.1)
7. Fan Wu†, Yanli Li† (co-first authors), Yun Meng†, Xuechao Cai, Jieyun Shi, Jinjin Li, Yang Chen, Li Zhang, Xianfu Meng, Huiyan Li, Xingwu Jiang, Zhenxiao Fu, Yelin Wu*, and Wenbo Bu*. An Ion-Enhanced Oncolytic Virus-Like Nanoparticle for Tumor Immunotherapy, Angew. Chem. Int. Ed., 2022, 61, e202210487. (IF=16.1)
8. Teng Gong†, Yanli Li† (co-first authors), Bin Lv†, Han Wang, Weiqiang Ge, Yanyan Liu*, Wei Yang, Yelin Wu, Xingwu Jiang, Hongbo Gao, Xiangpeng Zheng*, and Wenbo Bu*. Full-Process Radiosensitization Based on Nanoscale Metal-Organic Frameworks, ACS Nano, 2020, 14, 3032-3040. (IF=15.8)
9. Yelin Wu†, Yanli Li† (co-first authors), Guanglei Lv*, and Wenbo Bu*. Redox Dyshomeostasis Strategy for Tumor Therapy Based on Nanomaterials Chemistry, Chem. Sci., 2022, 13, 2202-2217. (IF=7.6)
10. Yanli Li† (co-first authors), Xiaonan Gao†, Zhengze Yu, Bo Liu, Wei Pan, Na Li*, and Bo Tang*. Reversing Multidrug Resistance by Multiplexed Gene Silencing for Enhanced Breast Cancer Chemotherapy, ACS Appl. Mater. Interfaces, 2018, 10, 15461-15466. (IF=8.3)
11. Na Li†, Yanli Li† (co-first authors), Xiaonan Gao, Zhengze Yu, Wei Pan, and Bo Tang*. Multiplexed gene silencing in living cells and in vivo using a DNAzymes–CoOOH nanocomposite, Chem. Commun., 2017, 53, 4962-4965. (IF=4.3)
